Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC.ACHV · Entity 5072 | Director | July 27, 2026 | July 29, 2026 |
| Adhera Therapeutics, Inc.ATRX · Entity 127789 | Director · CEO and Secretary | April 04, 2019 | April 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACHIEVE LIFE SCIENCES, INC.
Report date July 27, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.18 · Expires 2036-07-27 | Direct | 25,000 |
Reported balance
After 2026-07-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-27 · Grant · Acquired 25,000 · Balance 25,000 F1: The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2036-07-27 | Direct | 16,700 |
Reported balance
After 2026-07-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-27 · Grant · Acquired 16,700 · Balance 16,700 F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement. F3: Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement.
F3: Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
Adhera Therapeutics, Inc.
Report date April 04, 2019 · Filed April 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.37 · Expires 2029-04-04 | Direct | 1,500,000 |
Reported balance
After 2019-04-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-04-04 · Grant · Acquired 1,500,000 · Balance 1,500,000 F1: Options to purchase 400,000 shares of common stock vested on April 4, 2019, options to purchase 600,000 shares of common stock shall vest in equal monthly installments over a two year period beginning on April 4, 2020, options to purchase 250,000 shares of common stock shall vest on such date (if any) that the Issuer determines that the reporting person has earned the "2019 Revenue Bonus" (as defined in the Employment Agreement dated April 4, 2019 by and between the Issuer and the reporting person (the "Employment Agreement")), and options to purchase 250,000 shares of common stock shall vest on such date (if any) that the Issuer determines that the reporting person has earned the "2019 Stock Price Bonus" (as defined in the Employment Agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 400,000 shares of common stock vested on April 4, 2019, options to purchase 600,000 shares of common stock shall vest in equal monthly installments over a two year period beginning on April 4, 2020, options to purchase 250,000 shares of common stock shall vest on such date (if any) that the Issuer determines that the reporting person has earned the "2019 Revenue Bonus" (as defined in the Employment Agreement dated April 4, 2019 by and between the Issuer and the reporting person (the "Employment Agreement")), and options to purchase 250,000 shares of common stock shall vest on such date (if any) that the Issuer determines that the reporting person has earned the "2019 Stock Price Bonus" (as defined in the Employment Agreement).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2026 Filed Jul 29, 2026 21:17 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantRestricted Stock Unit (RSU) · Derivative | 16,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-324231 · ownership.xml · derivative · entry 2 Phelan Nancy R. · CIK 0001750316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,700 Underlying: Common Stock · 16,700 shares Expires 2036-07-27 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement. F3 · derivative.exercise_date: Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 21:17 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0001193125-26-324231 · ownership.xml · derivative · entry 1 Phelan Nancy R. · CIK 0001750316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-07-27 F1 · derivative.exercise_date: The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:58 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 31,500 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0000950170-25-084427 · ownership.xml · derivative · entry 1 Phelan Nancy R. · CIK 0001750316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2035-06-06 F1 · derivative.exercise_date: The options vest 100% on the earlier of June 6, 2026 or the date immediately prior to the Issuer's 2026 annual meeting of stockholders. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 21:46 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 47,250 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0000950170-25-005404 · ownership.xml · derivative · entry 1 Phelan Nancy R. · CIK 0001750316 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,250 Underlying: Common Stock · 47,250 shares Expires 2035-01-13 F1 · derivative.exercise_date: The option will vest in substantially equal monthly installments over 36 months commencing January 6, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 04, 2019 Filed Apr 4, 2019 18:50 UTC | Adhera Therapeutics, Inc. ATRX · Entity 127789 | GrantOptions to purchase common stock · Derivative | 1,500,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001750316-19-000001 · primary_doc.xml · derivative · entry 1 Phelan Nancy R. · CIK 0001750316 · Director · CEO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: common stock · 1,500,000 shares Expires 2029-04-04 F1 · derivative.exercise_date: Options to purchase 400,000 shares of common stock vested on April 4, 2019, options to purchase 600,000 shares of common stock shall vest in equal monthly installments over a two year period beginning on April 4, 2020, options to purchase 250,000 shares of common stock shall vest on such date (if any) that the Issuer determines that the reporting person has earned the "2019 Revenue Bonus" (as defined in the Employment Agreement dated April 4, 2019 by and between the Issuer and the reporting person (the "Employment Agreement")), and options to purchase 250,000 shares of common stock shall vest on such date (if any) that the Issuer determines that the reporting person has earned the "2019 Stock Price Bonus" (as defined in the Employment Agreement). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.